Ivabradine
Ivabradine, sold as Corlanor, is a medicine taken by mouth that the US label describes as a hyperpolarization-activated cyclic nucleotide-gated channel blocker, a drug that acts on a current in the natural pacemaker of the heart. The label read lists two uses: to reduce the risk of hospitalization for worsening heart failure in adults with stable, symptomatic chronic heart failure and a reduced left ventricular ejection fraction (35% or less, in sinus rhythm with a resting heart rate of 70 beats per minute or more, and already on the most beta-blocker they tolerate or unable to take one); and stable symptomatic heart failure due to dilated cardiomyopathy in children aged 6 months and older who are in sinus rhythm with an elevated heart rate.
Also called Corlanor
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 1649480; the label names the hydrochloride salt (RxNorm 1649479, UNII TP19837BZK, a broad match to the ingredient). MeSH D000077550 is Ivabradine. RxClass lists the FDA established pharmacologic class Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker; the atlas has no page for that class, so the record has no class parent. The label read is the Amgen Inc label for Corlanor, applications NDA206143 and NDA209964, effective 2026-11-09 in openFDA. Generic ivabradine labels were not read. The adult and pediatric statements sit in separate claims and contexts. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says it blocks the channel responsible for the cardiac pacemaker current, which regulates heart rate.
Classification codes
-
TP19837BZK
Claims and evidence
Context Adults with stable, symptomatic chronic heart failure and reduced ejection fraction, as described in the US label of Corlanor
- Recipient
- Adult
- Population
- Adult patients with stable, symptomatic chronic heart failure with a left ventricular ejection fraction of 35% or less, in sinus rhythm with a resting heart rate of 70 beats per minute or more, who either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use, as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the label states
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Adults with stable, symptomatic chronic heart failure and left ventricular ejection fraction of 35% or less
- In sinus rhythm with a resting heart rate of 70 beats per minute or more
- On maximally tolerated doses of beta-blockers or with a contraindication to beta-blocker use
- Excluded
- None stated
The US label of Corlanor (ivabradine, Amgen Inc, applications NDA206143 and NDA209964; the version dated 2026-11-09 in openFDA) describes ivabradine as a hyperpolarization-activated cyclic nucleotide-gated channel blocker. It lists reducing the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure whose left ventricular ejection fraction is 35% or lower, who are in sinus rhythm with a resting heart rate of 70 beats per minute or more and either are on maximally tolerated doses of beta-blockers or cannot take a beta-blocker.
Applies to Adult Adults with stable, symptomatic chronic heart failure and reduced ejection fraction, as described in the US label of Corlanor
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for in adults. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The pediatric use is in a separate claim. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], 1. INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2026-11-09
- Source state
- Current
- Version fingerprint
88339271a01e92bda6c7f7593d91fe219c336ce714748e5cc2c292f233414f5d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.1 Heart Failure in Adult Patients
- How it applies
- Label passage quoted in the research quote table (LB-05, LB-06, LB-07).
- Retrieved
- Source effective date
- 2026-11-09
- Source state
- Current
- Version fingerprint
88339271a01e92bda6c7f7593d91fe219c336ce714748e5cc2c292f233414f5d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20261109.
- Retrieved
- Source effective date
- 2026-11-09
- Source state
- Current
- Version fingerprint
88339271a01e92bda6c7f7593d91fe219c336ce714748e5cc2c292f233414f5d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Children aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy, as described in the US label of Corlanor
- Recipient
- Child
- Population
- Pediatric patients aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy who are in sinus rhythm with an elevated heart rate, as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Pediatric patients aged 6 months and older, as the label states
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Pediatric patients aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy, in sinus rhythm with an elevated heart rate
- Excluded
- None stated
The US label of Corlanor (ivabradine, Amgen Inc, applications NDA206143 and NDA209964; the version dated 2026-11-09 in openFDA) lists the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients aged 6 months and older who are in sinus rhythm with an elevated heart rate.
Applies to Child Children aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy, as described in the US label of Corlanor
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says about pediatric patients. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The adult indication is recorded in a separate claim. The label's pediatric use, dosing and safety sections were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1.2 Heart Failure in Pediatric Patients
- How it applies
- Label passage quoted in the research quote table (LB-08, and LB-10 for the sinus rhythm and heart rate condition).
- Retrieved
- Source effective date
- 2026-11-09
- Source state
- Current
- Version fingerprint
88339271a01e92bda6c7f7593d91fe219c336ce714748e5cc2c292f233414f5d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20261109.
- Retrieved
- Source effective date
- 2026-11-09
- Source state
- Current
- Version fingerprint
88339271a01e92bda6c7f7593d91fe219c336ce714748e5cc2c292f233414f5d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In newborns, infants and children 1
The US label of Corlanor (ivabradine, Amgen Inc, applications NDA206143 and NDA209964; the version dated 2026-11-09 in openFDA) lists the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients aged 6 months and older who are in sinus rhythm with an elevated heart rate.
Applies to Child Children aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy, as described in the US label of Corlanor
Population, setting and follow-up
- Pediatric patients aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy who are in sinus rhythm with an elevated heart rate, as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Pediatric patients aged 6 months and older, as the label states
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says about pediatric patients. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The adult indication is recorded in a separate claim. The label's pediatric use, dosing and safety sections were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1.2 Heart Failure in Pediatric Patients
- How it applies
- Label passage quoted in the research quote table (LB-08, and LB-10 for the sinus rhythm and heart rate condition).
- Retrieved
- Source effective date
- 2026-11-09
- Source state
- Current
- Version fingerprint
88339271a01e92bda6c7f7593d91fe219c336ce714748e5cc2c292f233414f5d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20261109.
- Retrieved
- Source effective date
- 2026-11-09
- Source state
- Current
- Version fingerprint
88339271a01e92bda6c7f7593d91fe219c336ce714748e5cc2c292f233414f5d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists reducing the risk of hospitalization for worsening heart failure in adults with chronic heart failure and a reduced left ventricular ejection fraction as an indication: Heart failure with reduced ejection fraction (HFrEF)
Applies to Adult Adults with stable, symptomatic chronic heart failure and reduced ejection fraction, as described in the US label of Corlanor
The US label of Corlanor (ivabradine, Amgen Inc, applications NDA206143 and NDA209964; the version dated 2026-11-09 in openFDA) describes ivabradine as a hyperpolarization-activated cyclic nucleotide-gated channel blocker. It lists reducing the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure whose left ventricular ejection fraction is 35% or lower, who are in sinus rhythm with a resting heart rate of 70 beats per minute or more and either are on maximally tolerated doses of beta-blockers or cannot take a beta-blocker.Limitations. This claim records what one US label says the medicine is indicated for in adults. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The pediatric use is in a separate claim. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients aged 6 months and older who are in sinus rhythm with an elevated heart rate as an indication: Dilated cardiomyopathy
Applies to Child Children aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy, as described in the US label of Corlanor
The US label of Corlanor (ivabradine, Amgen Inc, applications NDA206143 and NDA209964; the version dated 2026-11-09 in openFDA) lists the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients aged 6 months and older who are in sinus rhythm with an elevated heart rate.Limitations. This claim records what the label says about pediatric patients. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The adult indication is recorded in a separate claim. The label's pediatric use, dosing and safety sections were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:ivabradine- Content hash
fd6a76401d1c6b045926e2bdb33f9ea0baa0b32ac31673d19af645960e4b1dab